Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
AML clinical trials
Every US clinical trial registered for AML — phase mix, recruiting status, and the sponsors running them, straight from the NIH ClinicalTrials.gov registry.
28 US clinical trials · 16 currently recruiting
The research picture
AML has 28 registered US clinical trials, 16 of them open to new participants right now — about 57% of the total.
- 16
- recruiting participants now
- 57%
- of trials open to enrollment
- 1
- in Phase 3–4 (later-stage)
- 3
- top sponsor: M.D. Anderson Cancer Center
Counts reflect the public ClinicalTrials.gov registry as last mirrored by PlainTrial. Status and phase are reported by each study's sponsor. This is reference information, not medical advice.
Active & Recent Trials
Familial Investigations of Childhood Cancer Predisposition
St. Jude Children's Research Hospital
NCT03050268
A Long Term Follow-up Study of TScan TCR-T Products
TScan Therapeutics
NCT06976736
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Kura Oncology
NCT06001788
A Randomized Study to Compare Post-transplant Cyclophosphamide, Sirolimus, Ruxolitinib and Post-transplant Cyclophosphamide, Sirolimus, Mycophenolate Mofetil to Prevent Graft Versus Host Disease
M.D. Anderson Cancer Center
NCT06973668
A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation
TScan Therapeutics
NCT05473910
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Masonic Cancer Center, University of Minnesota
NCT05735717
Cardioprotection in AML
University of Virginia
NCT04977180
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
University of Rochester
NCT03739502
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Therapeutic Advances in Childhood Leukemia Consortium
NCT05476770
UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
University of Alabama at Birmingham
NCT06047886
CC-486 and Venetoclax for Acute Myeloid Leukemia
University of Colorado, Denver
NCT05287568
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
Memorial Sloan Kettering Cancer Center
NCT04644016
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Children's Hospital Medical Center, Cincinnati
NCT06131801
Revumenib in Combination With 7+3 + Midostaurin in AML
Richard Stone, MD
NCT06313437
CER-1236 in Patients With Acute Myeloid Leukemia (AML)
CERo Therapeutics Holdings
NCT06834282
Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced MDS and AML
Immune System Key
NCT04365179
Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia
Actinium Pharmaceuticals
NCT02665065
A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML
Treadwell Therapeutics
NCT04730258
A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure
M.D. Anderson Cancer Center
NCT05285813
ALLG AMLM26 INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML): A Multi-arm, Precision-based, Recursive, Platform Trial
M.D. Anderson Cancer Center
NCT06664879
Study of Bexarotene in Patients With Acute Myeloid Leukemia
Abramson Cancer Center at Penn Medicine
NCT00316030
Ascorbic Acid Levels in MDS, AML, and CMML Patients
Van Andel Research Institute
NCT03526666
Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies
National Cancer Institute (NCI)
NCT00013533
A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML
H. Lee Moffitt Cancer Center and Research Institute
NCT02403310
DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2
Celyad Oncology
NCT03466320
Sirolimus in Combination With MEC in High Risk Myeloid Leukemias
Abramson Cancer Center at Penn Medicine
NCT00780104
CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS
Cyclacel Pharmaceuticals
NCT04017546
Decitabine Maintenance in Elderly Acute Myeloid Leukemia Patients
University of Utah
NCT01149408
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 17 |
| Phase 2 | 6 |
| Phase 3 | 1 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Reading the AML Trial Landscape
ClinicalTrials.gov lists 28 US studies indexed under AML, and 16 of those are currently open to recruitment — roughly 57% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.
The phase distribution for AML shows 1 late-stage studies (Phase 3 and Phase 4 combined) alongside 23 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.
Top sponsor activity for AML is led by M.D. Anderson Cancer Center with 3 indexed trials, alongside 9 other organizations in the top contributor list. The list on this page surfaces up to 28 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.
Frequently Asked Questions
How many clinical trials are there for AML?
PlainTrial tracks 28 US clinical trials for AML, of which 16 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for AML?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.